Publication:
Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Placeholder

Organizational Units

Program

Authors

Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source:

Keywords:

Keywords

Citation

Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads


Sustainable Development Goals